Home › Research › Prevention and risk
Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective
Mielke MM, Aggarwal NT, Vila-Castelar C, Agarwal P, Arenaza-Urquijo EM, Brett B, Brugulat-Serrat A, DuBose LE et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022-04-08
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD) differ by world region, suggesting that there are potentially modifiable risk factors for intervention. However, few epidemiological or clinical ADRD studies examine sex differences; even fewer evaluate gender in the context of ADRD risk. The goals of this perspective are to: (1) provide definitions of gender, biologic sex, and sexual orientation. and the limitations of examining these as binary variables; (2) provide an overview of what is known with regard to sex and gender differences in the risk, prevention, and diagnosis of ADRD; and (3) discuss these sex and gender differences from a global, worldwide perspective. Identifying drivers of sex and gender differences in ADRD throughout the world is a first step in developing interventions unique to each geographical and sociocultural area to reduce these inequities and to ultimately reduce global ADRD risk. HIGHLIGHTS: The burden of dementia is unevenly distributed geographically and by sex and gender. Scientific advances in genetics and biomarkers challenge beliefs that sex is binary. Discrimination against women and sex and gender minority (SGM) populations contributes to cognitive decline. Sociocultural factors lead to gender inequities in Alzheimer's disease and related dementias (ADRD) worldwide.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mielke, M. M., Aggarwal, N. T., Vila-Castelar, C., Agarwal, P., Arenaza-Urquijo, E. M., Brett, B., et al. (2022). Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.12662
Vancouver
Mielke MM, Aggarwal NT, Vila-Castelar C, Agarwal P, Arenaza-Urquijo EM, Brett B, et al. Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022. doi:10.1002/alz.12662. PMID: 35394117.
BibTeX
@article{mielke2022-35394117,
author = {Mielke, M. M. and Aggarwal, N. T. and Vila-Castelar, C. and Agarwal, P. and Arenaza-Urquijo, E. M. and Brett, B. and Brugulat-Serrat, A. and DuBose, L. E. and others},
title = {{Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2022},
doi = {10.1002/alz.12662},
pmid = {35394117},
url = {https://doi.org/10.1002/alz.12662}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD) differ by world region, suggesting that there are potentially modifiable risk factors for intervention.
Why it matters
This perspective notes that sex and gender differences in Alzheimer's disease and related dementias risk vary by world region, suggesting potentially modifiable risk factors, and that discrimination against women and sex and gender minority populations contributes to cognitive decline. It calls for identifying drivers of these differences as a first step toward tailored interventions, not a proven treatment.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthLow
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 53 of the 96 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 195 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 32.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 5 / 6 | Cited 21.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 24 other studies in this library |
| Still being cited | 3 / 4 | Cited 156 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 35 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35394117) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 53 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 53 of the 96 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 47.
Later studies that cite this one
24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Prevention and risk from nearby years
Also in Prevention and risk
269 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.